Horizon Kinetics Asset Management LLC Lowers Holdings in Danaher Corporation $DHR

Horizon Kinetics Asset Management LLC lessened its stake in Danaher Corporation (NYSE:DHR) by 15.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,884 shares of the conglomerate’s stock after selling 860 shares during the quarter. Horizon Kinetics Asset Management LLC’s holdings in Danaher were worth $965,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in DHR. Red Tortoise LLC increased its stake in Danaher by 175.0% during the second quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock worth $30,000 after acquiring an additional 98 shares during the last quarter. Ramirez Asset Management Inc. acquired a new stake in Danaher during the 2nd quarter worth approximately $40,000. Costello Asset Management INC purchased a new position in Danaher in the first quarter valued at approximately $41,000. Strengthening Families & Communities LLC grew its stake in Danaher by 81.4% during the first quarter. Strengthening Families & Communities LLC now owns 254 shares of the conglomerate’s stock worth $52,000 after buying an additional 114 shares during the period. Finally, Saudi Central Bank acquired a new stake in shares of Danaher in the first quarter worth $52,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Stock Down 0.2%

Shares of NYSE:DHR opened at $227.05 on Tuesday. The company’s fifty day moving average is $209.36 and its two-hundred day moving average is $202.34. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $258.23. The stock has a market capitalization of $160.38 billion, a price-to-earnings ratio of 46.81, a price-to-earnings-growth ratio of 3.28 and a beta of 0.81.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. The business had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $6 billion. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.71 EPS. Equities analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Friday, September 26th were given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Friday, September 26th. Danaher’s dividend payout ratio is presently 26.39%.

Analysts Set New Price Targets

Several analysts recently issued reports on DHR shares. Rothschild Redb downgraded Danaher from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 8th. Royal Bank Of Canada set a $241.00 price objective on shares of Danaher in a research report on Tuesday, September 2nd. Bank of America dropped their price target on shares of Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a research note on Monday, September 22nd. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Danaher from $235.00 to $250.00 and gave the company a “buy” rating in a research report on Wednesday, October 22nd. Finally, JPMorgan Chase & Co. boosted their price target on Danaher from $260.00 to $270.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 22nd. Eighteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $243.39.

Insider Buying and Selling

In other Danaher news, SVP Brian W. Ellis sold 21,776 shares of the firm’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the sale, the senior vice president directly owned 14,553 shares in the company, valued at approximately $3,190,454.19. This trade represents a 59.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Teri List sold 3,298 shares of the business’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total transaction of $746,997.00. Following the transaction, the director directly owned 20,762 shares of the company’s stock, valued at approximately $4,702,593. This trade represents a 13.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 30,248 shares of company stock valued at $6,609,663. Insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.